Preoperative Gastric Volume and High-Risk Gastric Content in Patients With Type 2 Diabetes Mellitus
Clinical and Metabolic Determinants of High Residual Gastric Volume in Patients With Type 2 Diabetes Mellitus
This prospective observational study will evaluate adult patients with type 2 diabetes mellitus who are scheduled for elective surgery. Immediately before preoperative gastric ultrasonography, capillary fasting blood glucose will be measured.
Gastric contents will be assessed qualitatively in the supine and right lateral decubitus positions, and residual gastric volume will be estimated using the antral cross-sectional area measured in the right lateral decubitus position.
The primary objective is to evaluate the association between fasting capillary blood glucose and the presence of a high-risk stomach. A high-risk stomach will be defined as the presence of solid gastric contents, Perlas Grade 2 gastric contents, or an estimated gastric volume greater than 1.5 mL/kg.
Secondary objectives include determining the prevalence of a high-risk stomach and evaluating its associations with demographic characteristics, diabetes-related factors, comorbidities, fasting duration, medication use, gastroparesis-related symptoms, and routine laboratory parameters.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This is a single-center, prospective observational study involving adult patients with type 2 diabetes mellitus scheduled for elective surgery.
On the day of surgery, participants will be evaluated in the preoperative preparation area before anesthesia induction and before administration of sedative premedication. Demographic data, diabetes duration and treatment, diabetes-related complications, comorbidities, smoking status, symptoms potentially associated with gastroparesis, fasting duration, and routinely available laboratory parameters will be recorded.
Capillary fasting blood glucose will be measured immediately before gastric ultrasonography and will constitute the primary independent variable.
Gastric ultrasonography will be performed by a trained and experienced investigator using a low-frequency convex transducer. The gastric antrum will be assessed first in the supine position and then in the right lateral decubitus position. Gastric contents will be classified as empty, clear fluid, or solid content. Clear fluid findings will additionally be classified according to the Perlas grading system.
For quantitative assessment, anteroposterior and craniocaudal diameters of the gastric antrum will be measured and the antral cross-sectional area will be calculated. Estimated gastric volume will be calculated from the right lateral decubitus antral cross-sectional area and expressed both in mL and mL/kg.
A high-risk stomach will be defined by at least one of the following findings: solid gastric contents, clear fluid visible in both the supine and right lateral decubitus positions (Perlas Grade 2), or estimated gastric volume greater than 1.5 mL/kg.
No experimental treatment or additional invasive intervention will be administered as part of the study. If clinically relevant high-risk gastric findings are identified, the responsible anesthesia team will be informed and subsequent anesthetic management will be determined by the clinical team.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Fatma Çiğdem Özakın, MD
- Numéro de téléphone: +905464168250
- E-mail: f.cigdemulus@gmail.com
Lieux d'étude
-
-
Istanbul
-
Istanbul, Istanbul, Turquie (Türkiye), 34147
- Bakırköy Dr. Sadi Konuk Training and Research Hospital
-
Contact:
- Fatma Çiğdem Özakın, MD
- Numéro de téléphone: +905464168250
- E-mail: f.cigdemulus@gmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Adult patients with type 2 diabetes mellitus who are scheduled for elective surgery at University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital and who meet the study eligibility criteria.
La description
Inclusion Criteria:
- Age 18 years or older
- Diagnosis of type 2 diabetes mellitus
- American Society of Anesthesiologists (ASA) physical status II or III
- Scheduled for elective surgery
- Suitable for preoperative gastric ultrasonography
- Provision of written informed consent
Exclusion Criteria:
- Pregnancy
- Body mass index ≥40 kg/m²
- Emergency surgery
- History of gastric, esophageal, or upper gastrointestinal surgery
- Presence of a nasogastric tube
- Known gastroparesis or gastric outlet obstruction
- Active vomiting
- Systemic opioid or prokinetic drug use within the previous 72 hours
- Anatomical or technical conditions preventing adequate gastric ultrasonographic assessment
- Impaired consciousness or inability to provide a reliable medical history
- Refusal to participate in the study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Preoperative Patients With Type 2 Diabetes Mellitus
Adult patients with type 2 diabetes mellitus, ASA physical status II or III, who are scheduled for elective surgery and undergo preoperative gastric ultrasonography and capillary fasting blood glucose measurement. |
The gastric antrum will be evaluated in the supine and right lateral decubitus positions before anesthesia induction and sedative premedication. Gastric contents will be assessed qualitatively, and antral cross-sectional area and estimated residual gastric volume will be calculated quantitatively. Capillary fasting blood glucose will be measured by fingertip sampling immediately before gastric ultrasonography. The measured glucose concentration will be evaluated as the primary exposure variable in relation to high-risk gastric findings. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Presence of a High-Risk Stomach
Délai: On the day of surgery, during the preoperative assessment immediately before anesthesia induction
|
A high-risk stomach will be defined as the presence of at least one of the following findings on preoperative gastric ultrasonography: solid gastric contents; clear fluid visible in both the supine and right lateral decubitus positions (Perlas Grade 2); or an estimated gastric volume greater than 1.5 mL/kg. |
On the day of surgery, during the preoperative assessment immediately before anesthesia induction
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Association Between Age and High-Risk Stomach
Délai: On the day of surgery, during the preoperative assessment before anesthesia induction
|
Age will be recorded in years from the patient's medical record. The association between age and the presence of a high-risk stomach (yes/no) will be evaluated . |
On the day of surgery, during the preoperative assessment before anesthesia induction
|
|
Association Between Sex and High-Risk Stomach
Délai: On the day of surgery, during the preoperative assessment before anesthesia induction
|
Sex will be recorded as male or female from the patient's medical record. The association between sex and the presence of a high-risk stomach (yes/no) will be evaluated. |
On the day of surgery, during the preoperative assessment before anesthesia induction
|
|
Association Between Body Mass Index and High-Risk Stomach
Délai: On the day of surgery, during the preoperative assessment before anesthesia induction
|
Body mass index will be calculated as body weight in kilograms divided by height in meters squared and reported in kg/m². The association between body mass index and the presence of a high-risk stomach (yes/no) will be evaluated. |
On the day of surgery, during the preoperative assessment before anesthesia induction
|
|
Association Between Duration of Type 2 Diabetes Mellitus and High-Risk Stomach
Délai: On the day of surgery, during the preoperative assessment before anesthesia induction
|
Duration of type 2 diabetes mellitus will be recorded in years based on the patient's medical history and medical records. Its association with the presence of a high-risk stomach (yes/no) will be evaluated. |
On the day of surgery, during the preoperative assessment before anesthesia induction
|
|
Association Between Diabetes-Related Complications and High-Risk Stomach
Délai: On the day of surgery, during the preoperative assessment before anesthesia induction
|
The presence of diabetes related target organ complications will be determined from the patient's medical history and medical records and recorded as present or absent. The association between the presence of diabetes-related complications and a high-risk stomach (yes/no) will be evaluated. |
On the day of surgery, during the preoperative assessment before anesthesia induction
|
|
Association Between Comorbidities and High-Risk Stomach
Délai: On the day of surgery, during the preoperative assessment before anesthesia induction
|
The presence of comorbidity will be assessed from the patient's medical history and medical records. Prespecified comorbidities will include hypertension, gastroesophageal reflux disease, obstructive sleep apnea, hypothyroidism, chronic kidney disease, dialysis treatment, and liver dysfunction. Participants will be classified according to the presence or absence of at least one of these comorbidities. The association between the presence of any prespecified comorbidity and a high-risk stomach (yes/no) will be evaluated. |
On the day of surgery, during the preoperative assessment before anesthesia induction
|
|
Association Between Gastroparesis-Related Symptoms and High-Risk Stomach
Délai: On the day of surgery, during the preoperative assessment before anesthesia induction
|
Gastroparesis-related symptoms will be assessed by preoperative patient interview. Prespecified symptoms will include loss of appetite, early satiety, and postprandial fullness. Participants will be classified according to the presence or absence of at least one of these symptoms. The association between the presence of any gastroparesis-related symptom and a high-risk stomach (yes/no) will be evaluated. |
On the day of surgery, during the preoperative assessment before anesthesia induction
|
|
Association Between Solid Food Fasting Duration and High-Risk Stomach
Délai: On the day of surgery, during the preoperative assessment before anesthesia induction
|
The time elapsed since the last solid food intake will be determined from the patient's history and clinical records and recorded in hours. Its association with the presence of a high-risk stomach (yes/no) will be evaluated. |
On the day of surgery, during the preoperative assessment before anesthesia induction
|
|
Association Between Clear Fluid Fasting Duration and High-Risk Stomach
Délai: On the day of surgery, during the preoperative assessment before anesthesia induction
|
The time elapsed since the last clear fluid intake will be determined from the patient's history and clinical records and recorded in hours. Its association with the presence of a high-risk stomach (yes/no) will be evaluated. |
On the day of surgery, during the preoperative assessment before anesthesia induction
|
|
Association Between Smoking Status and High-Risk Stomach
Délai: On the day of surgery, during the preoperative assessment before anesthesia induction
|
Smoking status will be assessed by patient interview and categorized as current smoker, former smoker, or never smoker. The association between smoking status and the presence of a high-risk stomach (yes/no) will be evaluated. |
On the day of surgery, during the preoperative assessment before anesthesia induction
|
|
Association Between Antidiabetic Medication Use and High-Risk Stomach
Délai: On the day of surgery, during the preoperative assessment before anesthesia induction
|
Current antidiabetic medication use will be determined from the patient's medication history and medical records. Antidiabetic medications will include oral antidiabetic drugs, insulin, GLP-1 receptor agonists, and SGLT-2 inhibitors. Participants will be classified according to the presence or absence of current use of at least one antidiabetic medication. The association between any current antidiabetic medication use and the presence of a high-risk stomach (yes/no) will be evaluated. |
On the day of surgery, during the preoperative assessment before anesthesia induction
|
|
Association Between Proton Pump Inhibitor Use and High-Risk Stomach
Délai: On the day of surgery, during the preoperative assessment before anesthesia induction
|
Proton pump inhibitor use will be determined from the patient's medication history and recorded as yes or no. Its association with the presence of a high-risk stomach (yes/no) will be evaluated. |
On the day of surgery, during the preoperative assessment before anesthesia induction
|
|
Association Between HbA1c and High-Risk Stomach
Délai: On the day of surgery, during the preoperative assessment before anesthesia induction
|
HbA1c will be obtained from routine preoperative laboratory results and recorded as a percentage (%). The association between HbA1c and the presence of a high-risk stomach (yes/no) will be evaluated. |
On the day of surgery, during the preoperative assessment before anesthesia induction
|
|
Association Between Hemoglobin Level and High-Risk Stomach
Délai: On the day of surgery, during the preoperative assessment before anesthesia induction
|
Hemoglobin concentration will be obtained from routine preoperative laboratory results and recorded in g/dL. The association between hemoglobin concentration and the presence of a high-risk stomach (yes/no) will be evaluated. |
On the day of surgery, during the preoperative assessment before anesthesia induction
|
|
Association Between Blood Urea Level and High-Risk Stomach
Délai: On the day of surgery, during the preoperative assessment before anesthesia induction
|
Blood urea concentration will be obtained from routine preoperative laboratory results and recorded in mg/dL. The association between blood urea concentration and the presence of a high-risk stomach (yes/no) will be evaluated. |
On the day of surgery, during the preoperative assessment before anesthesia induction
|
|
Association Between Serum Creatinine Level and High-Risk Stomach
Délai: On the day of surgery, during the preoperative assessment before anesthesia induction
|
Serum creatinine concentration will be obtained from routine preoperative laboratory results and recorded in mg/dL. The association between serum creatinine concentration and the presence of a high-risk stomach (yes/no) will be evaluated. |
On the day of surgery, during the preoperative assessment before anesthesia induction
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Fatma Çiğdem Özakın, MD, Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Publications et liens utiles
Publications générales
- Kar Man Chan L. Gastric ultrasound: Enhancing preoperative risk assessment and patient safety. J Perioper Pract. 2025 Nov;35(11):501-503. doi: 10.1177/17504589241302220. Epub 2024 Dec 11.
- Aydin BS, Guldogan IK. Determinants of gastric residual volume before elective surgery in diabetic patients: An observational study. Saudi J Anaesth. 2024 Apr-Jun;18(2):167-172. doi: 10.4103/sja.sja_339_23. Epub 2024 Mar 14.
- Perlas A, Xiao MZX, Tomlinson G, Jacob B, Abdullah S, Kruisselbrink R, Chan VWS. Baseline Gastric Volume in Fasting Diabetic Patients Is Not Higher than That in Nondiabetic Patients: A Cross-sectional Noninferiority Study. Anesthesiology. 2024 Apr 1;140(4):648-656. doi: 10.1097/ALN.0000000000004815.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2026/317
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .